Global private equity (PE) giants—Blackstone, Brookfield, and Warburg Pincus—are in advanced discussions to acquire a significant majority stake in Hyderabad-based Gland Pharma Ltd. The potential deal, valued at approximately $3 billion, marks a pivotal shift in ownership. Currently, China’s Shanghai Fosun Pharmaceutical Co. Ltd owns a controlling 51% stake in the company, but Fosun is exploring divestment in the wake of geopolitical and regulatory considerations.
With binding bids expected next month, this transaction stands to reshape Gland Pharma’s strategic direction while setting a historic benchmark for private equity investments in India’s pharmaceutical sector.
Gland Pharma’s Valuation and Fosun’s Exit Plan
Currently listed on the National Stock Exchange (NSE), Gland Pharma has a market capitalization of ₹23,901 crore ($2.8 billion). Fosun has been seeking to exit its stake in the company since 2020, driven by the increasing geopolitical tensions between India and China alongside shifting investment priorities.
Fosun originally secured its majority ownership in Gland Pharma back in 2017 by acquiring a 74% stake for $1.2 billion. However, it has been gradually reducing its holding since then. For instance, in June 2024, Fosun lowered its stake by offloading 6% of its shares for ₹1,754 crore ($172 million). By December 2024, Fosun’s shareholding further declined to 51.8%.
Plans for direct transaction with private equity firms could reduce Fosun’s stake even further, while also triggering an open offer to minority shareholders in Gland Pharma. Sources close to the deal speculate that the buyers could seek a controlling interest ranging between 60% and 65%.
Market reactions to the news have been steady, with shares of Gland Pharma seeing a 2.74% rise, reaching ₹1,491.55 on the NSE by mid-day on February 12.
While no official comments have been made by Fosun, Blackstone, Brookfield, Warburg Pincus, or the banks facilitating the transaction (Morgan Stanley and UBS), investor interest in this potential shift is palpable.
Gland Pharma’s Legacy and New Leadership
Founded in 1978 by P.V.N. Raju, Gland Pharma has grown to become a global powerhouse in the production of generic injectables. The company’s operations span over 90 countries, with strongholds in markets like India and the United States. Its strategic focus on generic injectable drugs has positioned it as a dependable player in the pharmaceutical ecosystem worldwide.
Adding to its forward momentum, the company recently appointed Shyamakant Giri as its Chief Executive Officer (CEO) in January 2025. Giri brings over two decades of experience in the pharmaceutical industry through roles at global firms like Amneal Pharmaceuticals. Under his guidance, Gland Pharma is expected to sharpen its focus on profitable new verticals, including contract development and manufacturing operations (CDMO) in biologics.
Financial Performance and Strategic Growth
Gland Pharma continues to demonstrate noteworthy financial stability. For the December 2024 quarter, the company reported revenues of ₹1,384 crore, an EBITDA of ₹360 crore (yielding a strong margin of 26%), and a profit after tax (PAT) of ₹204.7 crore, up from ₹191.9 crore for the same quarter the previous year.
One of the company’s strategic outlooks into its future lies in biologics. Executive Chairman Srinivas Sadu emphasized in a recent statement the company’s strategic expansion into biologics, a booming segment within global pharmaceuticals. “Our collaborations in the CDMO segment are expected to unlock significant opportunities in the fast-growing biologics space,” noted Sadu. He further stated that revenues from these initiatives should kick in during the next financial year.
Biologics—therapeutics produced from living organisms—fall within a high-value, specialized pharmaceutical category that aligns perfectly with the industry’s shift toward premium products. By prioritizing this segment through partnerships and R&D investments, Gland Pharma positions itself for substantial growth opportunities.
The Future of Gland Pharma
The ongoing bidding war among Blackstone, Brookfield, and Warburg Pincus represents more than just a change in shareholders; it signals a potential turning point in the trajectory of Gland Pharma. Fosun’s exit aligns with a broader global trend wherein Chinese firms are divesting stakes in Indian companies due to increasing regulatory scrutiny and geopolitical pressures.
For Gland Pharma, transitioning to private equity ownership is widely expected to bring more than just fresh capital. It could lead to intensified expansion strategies, deeper penetration into new markets, and strategic partnerships that align with emerging pharmaceutical trends like biologics and specialty drugs.
The buyer selection process is expected to conclude in the coming months, setting the tone for one of the largest private equity transactions in India’s pharmaceutical sector to date. Given the strong foundations and the exciting growth opportunities in high-value markets, Gland Pharma is positioned to remain a critical player in the global pharmaceutical industry.
What’s Next?
The acquisition process is entering its most critical phase, and the final decision could bring transformational changes to Gland Pharma. With growth efforts already underway in biologics and CDMO ventures, the backing of a global PE firm could further catalyze these endeavors.
For industry observers, the conclusion of this deal will not only redefine Gland Pharma’s ownership and strategy but also demonstrate the importance of private equity collaborations in shaping the future of pharmaceutical enterprises in India.
Stay tuned—this is one deal set to reshape the contours of the global pharmaceutical landscape.
Feel free to share your experiences and insights in the comments below. Let’s continue the conversation and grow together as a community of traders and analysts.
By sharing this experience and insights, I hope to contribute to the collective knowledge of our professional community, encouraging a culture of strategic thinking and informed decision-making.
As always, thorough research and risk management are crucial. The dynamic nature of financial markets demands vigilance, agility, and a deep understanding of the tools at your disposal. Here’s to profitable trading and navigating the election season with confidence!
Ready to stay ahead of market trends and make informed investment decisions? Follow our page for more insights and updates on the latest in the financial world!
For a free online stock market training by Yogeshwar Vashishtha (M.Tech IIT) this Saturday from 11 am – 1 pm, please sign up with https://pathfinderstrainings.in/training/freetrainings.aspx
Experience profits with my winning algo strategies – get a free one-month trial with ₹15 lakh capital! – https://www.terminal.algofinder.in/auth/register
Disclaimer
This article should not be interpreted as investment advice. For any investment decisions, consult a reputable financial advisor. The author and publisher are not responsible for any losses incurred by investors or traders based on the information provided.